Photo from wikipedia
Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have… Click to show full abstract
Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The benefit of VEN‐based therapy in patients who have newly diagnosed AML with mutations in the TP53 gene (TP53mut) over standard therapy is undefined.
Keywords:
patients newly;
newly diagnosed;
myeloid leukemia;
acute myeloid;
therapy;
based therapy
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!